PT-141 10mg research vial
PT-141, also called bremelanotide, is a close lab-made relative of MT-2; the 10mg vial sells for 3,600,000 VND ($140 USD). Its price was checked on 11 October 2026 by Peptides Ho Chi Minh, and its 2006 trial and two reviews each have a PubMed link. Under the name bremelanotide, PT-141 is the active part of a medicine first cleared in the United States in 2019. A drug profile below covers it. A research vial like this one is not that medicine, and no regulator has approved it for people.
What is PT-141?
PT-141 is a close relative of Melanotan II.
Research describes it as acting on receptors in the brain rather than on blood flow.
PT-141 trials and the doubts about them
- Human trial, 2006. 18 women before menopause with low arousal had bremelanotide and a placebo in turn, a crossover design. Each one reported her level of desire.
- Review, 2019. A drug profile covered the first approval in the United States of a medicine made with bremelanotide.
- Review, 2024. A review of the large phase 3 data looked at the size of the measured effects and at the scoring tools used.
Small early studies and two large phase 3 trials in women. A 2022 analysis of those two trials, in 1,202 women before menopause with low sexual desire, compared bremelanotide with a placebo over 24 weeks, using desire and distress scores. Read it next to the 2024 review above, which weighs those effects and scores.
How to read this
A medicine with bremelanotide, the research name for PT-141, as its active ingredient is approved in the United States, and two large phase 3 trials in women before menopause were run on it. The 2022 analysis split those trials by age and weight. The 2024 review looks hard at the size of the measured effects and at some scoring tools. Both are on this page on purpose.
The PT-141 paper trail
The 2006 study ran in the Journal of Sexual Medicine and used a crossover design, so each woman had both bremelanotide and a placebo. The 2019 drug profile appeared in Drugs, and the 2024 review in the Journal of Sex Research. Reading that review next to the trials keeps the record balanced.
Sources: PubMed record 16839319 (human trial, 2006); PubMed record 31429064 (review, 2019); PubMed record 36809187 (review, 2024); PubMed record 35230162 (2022 analysis of the phase 3 trials).
How much does PT-141 cost per pack?
| Pack | Price | Per vial | Per mg |
|---|---|---|---|
| 1 vial | 3,600,000 VND ($140 USD) | 3,600,000 VND ($140 USD) | 360,000 VND ($14 USD) |
| 3 vials | 8,748,000 VND ($340.20 USD) | 2,916,000 VND ($113.40 USD) | 291,600 VND ($11.34 USD) |
| 5 vials | 12,960,000 VND ($504 USD) | 2,592,000 VND ($100.80 USD) | 259,200 VND ($10.08 USD) |
| 10 vials | 21,600,000 VND ($840 USD) | 2,160,000 VND ($84 USD) | 216,000 VND ($8.40 USD) |
Questions about PT-141
What has research on PT-141 looked at?
Sexual desire in women before menopause. There are small studies and two large phase 3 trials. A 2024 review weighs how those trials were scored.
How is PT-141 related to MT-2?
PT-141, also called bremelanotide, is a close lab-made relative of MT-2. Both are rings of 7 amino acids, and research describes PT-141 as acting on receptors in the brain rather than on blood flow.
Is PT-141 the same as bremelanotide?
Yes. Bremelanotide is the drug name for PT-141, the same lab-made ring of 7 amino acids. A medicine made with it is approved in the United States, and the vial here is a research compound, not that medicine.
How many PubMed records cover bremelanotide?
110 on 18 October 2026, when we searched PubMed for bremelanotide. This page lists three of them: the 2006 trial in women before menopause and two reviews. We kept the critical 2024 review beside the trial on purpose, because the approval rests on two phase 3 trials in 1,202 women and that review argues their effects were small.
By Peptides Ho Chi Minh, 11 October 2026